648927-86-0
Chemical Structure
Firibastat
Synonym(s): QGC001; RB150
- CAS No.: 648927-86-0
- Formula:C8H20N2O6S4
- Molecular Weight:368.51
IUPAC Name: (S)-3-amino-4-(((S)-2-amino-4-sulfobutyl)disulfanyl)butane-1-sulfonic acid
InChIKey: HJPXZXVKLGEMGP-YUMQZZPRSA-N
SMILES: O=S(CC[C@H](N)CSSC[C@@H](N)CCS(=O)(O)=O)(O)=O
Biological Activity: Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Firibastat | 98.0% | Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Firibastat (Standard) | ≥98% | Firibastat (Standard) is the analytical standard of Firibastat. This product is intended for research and analytical applications. Firibastat (QGC001), an orally active brain penetrating proagent of EC33, is a first-in-class brain aminopeptidase A (APA) inhibitor (Ki=200 nM). Firibastat selectively and specifically inhibits conversion of brain angiotensin-II into angiotensin-III and decreases blood pressure in hypertensive rats. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ferdinand KC, et al. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins. Circulation. 2019;140(2):138-146. [Content Brief]
- [2]. Keck M, et al. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions. Curr Hypertens Rep. 2019;21(7):50. Published 2019 May 21. [Content Brief]
Keywords
